| Authors: |
Park M; Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge UK spring@ch.cam.ac.uk., Dannheim FM; Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge UK spring@ch.cam.ac.uk., Papworth MA; Oncology R&D, AstraZeneca UK., Kay R; Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge UK., Tsonou E; BioPharmaceuticals R&D, AstraZeneca UK., Trajkovski D; Department of Surgery, University of Cambridge UK., Walsh SJ; Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge UK spring@ch.cam.ac.uk., Hovdal D; Preclinical and Translational PK & PKPD Specialist (DMPK), AstraZeneca Gothenburg Sweden., Wharton T; Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge UK spring@ch.cam.ac.uk., Nassoy AC; Oncology R&D, AstraZeneca UK., Parker JS; Early Chemical Development, Pharmaceutical Development, R&D, AstraZeneca Macclesfield UK., Spring DR; Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge UK spring@ch.cam.ac.uk. |
